BACKGROUND: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. OBJECTIVE: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. DESIGN: One group (30 subjects) was supplemented with a single oral dose of 100,000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. RESULTS:Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 +/- 0.80 ng/mL during 4 mo. CONCLUSIONS:Cholecalciferol (100,000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be < or =2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials.gov as #NCT00473239.
RCT Entities:
BACKGROUND: There is much interest in dosing vitamin D intermittently for patient convenience and long-term adherence. OBJECTIVE: The objective was to characterize the time course and response of 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol. DESIGN: One group (30 subjects) was supplemented with a single oral dose of 100,000 IU cholecalciferol. A second group (10 subjects) served as a control group to assess the seasonal change of calcidiol. Serum calcidiol concentrations were followed for 4 mo. The subjects were healthy with limited sun exposure (<10 h/wk) and milk consumption (<0.47 L daily). We excluded subjects with granulomatous conditions, liver disease, kidney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids. RESULTS: Serum calcidiol rose promptly after cholecalciferol dosing from a mean (+/-SD) baseline of 27.1 +/- 7.7 ng/mL to a concentration maximum of 42.0 +/- 9.1 ng/mL. Seven percent of the supplemented cohort failed to achieve 32.1 ng/mL at any time point. The highest achieved concentration in any subject was 64.2 ng/mL. The control group had a nonsignificant change from baseline of -0.72 +/- 0.80 ng/mL during 4 mo. CONCLUSIONS:Cholecalciferol (100,000 IU) is a safe, effective, and simple way to increase calcidiol concentrations. The dosing interval should be < or =2 mo to ensure continuous serum calcidiol concentrations above baseline. This trial was registered at www.clinicaltrials.gov as #NCT00473239.
Authors: M Marzo; R Ciccarelli; P Di Iorio; P Giuliani; F Caciagli; A Marzo Journal: Int J Immunopathol Pharmacol Date: 2015-12-18 Impact factor: 3.219
Authors: Alanna S Ocampo-Pelland; Marc R Gastonguay; Jonathan F French; Matthew M Riggs Journal: J Pharmacokinet Pharmacodyn Date: 2016-02-12 Impact factor: 2.745
Authors: Michael L Traub; John S Finnell; Anup Bhandiwad; Erica Oberg; Lena Suhaila; Ryan Bradley Journal: J Clin Endocrinol Metab Date: 2014-03-31 Impact factor: 5.958
Authors: Etan Orgel; Nicole M Mueske; Richard Sposto; Vicente Gilsanz; Tishya A L Wren; David R Freyer; Anna M Butturini; Steven D Mittelman Journal: Leuk Lymphoma Date: 2017-02-20
Authors: M D Kearns; J N G Binongo; D Watson; J A Alvarez; D Lodin; T R Ziegler; V Tangpricha Journal: Eur J Clin Nutr Date: 2014-10-01 Impact factor: 4.016
Authors: H A Bischoff-Ferrari; A Shao; B Dawson-Hughes; J Hathcock; E Giovannucci; W C Willett Journal: Osteoporos Int Date: 2009-12-03 Impact factor: 4.507